This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Sticks to Its Buy Rating for Resmed (RMD)

Tipranks - Tipranks - Fri Jun 5, 6:04AM CDT

In a report released today, Lyanne Harrison from Bank of America Securities reiterated a Buy rating on Resmed, with a price target of $320.00.

Claim 55% Off TipRanks

According to TipRanks, Harrison is ranked #10518 out of 12227 analysts.

In addition to Bank of America Securities, Resmed also received a Buy from William Blair’s Brandon Vazquez in a report issued yesterday. However, on May 29, Wells Fargo assigned a Hold rating to Resmed (NYSE: RMD).

See Insiders’ Hot Stocks on TipRanks >>

Based on Resmed’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.43 billion and a net profit of $398.73 million. In comparison, last year the company earned a revenue of $1.29 billion and had a net profit of $365.04 million

Read More on RMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).